RAKOVINA THERAPEUTICS INC (RKVTF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Jeffrey A. Bacha B.Sc., M.B.A. | Executive Chairman | 89.23k | -- | 1968 |
| Dr. Mads Daugaard | President, CEO & Chief Scientific Officer | -- | -- | -- |
| Mr. David Hyman CA, CBV | CFO & Corporate Secretary | 89.23k | -- | 1973 |
| Dr. John Langlands Ph.D. | Chief Operating Officer | -- | -- | -- |
RAKOVINA THERAPEUTICS INC
- Sector:?
- Healthcare
- Industry:? Biotechnology
Description
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. Its preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada. Rakovina Therapeutics Inc. operates as a subsidiary of NewGen Therapeutics, Inc.
Corporate Governance
Upcoming Events
November 25, 2024 at 10:59 AM UTC - November 29, 2024 at 12:00 PM UTC
RAKOVINA THERAPEUTICS INC Earnings Date
Recent Events
Recent Events Information Not Available